HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Emesis and defecations induced by the 5-hydroxytryptamine (5-HT3) receptor antagonist zacopride in the ferret.

Abstract
Three antiemetic compounds (zacopride, batanopride, granisetron [BRL43694]) were evaluated for the production of gastrointestinal side effects in the conscious ferret after i.v. or p.o. administration. Zacopride evoked multiple emetic and defecatory responses at clinically relevant doses (0.003-0.3 mg/kg) and in a dose-dependent manner. The oral route was the more potent one for eliciting emesis (ED50 0.033 mg/kg). At 0.3 mg/kg p.o., zacopride reliably evoked an 80 to 100% incidence of emesis and a 40 to 80% incidence of defecation. In contrast, batanopride and BRL43694 i.v. evoked a small (10%) incidence of these side effects, but only at 0.1 to 10 mg/kg doses. When given p.o. (0.00003-10 mg/kg), these latter compounds never evoked emesis and significantly reduced (P less than .05) the incidence of defecation below that of vehicle. Responses to zacopride (0.3 mg/kg p.o.) were challenged by i.p. pretreatment with the 5-hydroxytryptamine receptor agonist 2-methyl serotonin, the 5-hydroxytryptamine receptor antagonist BRL43694, the quaternary atropine derivative glycopyrrolate, the dopamine receptor antagonist domperidone or selective abdominal vagotomies. All compounds and either bilateral or dorsal vagotomy significantly reduced the incidence of emesis, but did not abolish it. Latency to first emesis was delayed by BRL43694, domperidone or dorsal vagotomy. The data suggest that the emetic response to p.o. zacopride is mediated in part by 5-hydroxytryptamine receptors residing on either enteric neurons or vagal afferents. However, the underlying pharmacology of the response may also include activation of cholinergic and dopaminergic pathways.
AuthorsG L King
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 253 Issue 3 Pg. 1034-41 (Jun 1990) ISSN: 0022-3565 [Print] United States
PMID2162943 (Publication Type: Comparative Study, Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Antiemetics
  • Benzamides
  • Bridged Bicyclo Compounds
  • Bridged Bicyclo Compounds, Heterocyclic
  • Bridged-Ring Compounds
  • Indazoles
  • Pyrazoles
  • Serotonin Antagonists
  • batanopride
  • Serotonin
  • 2-methyl-5-HT
  • zacopride
  • Metoclopramide
  • Granisetron
Topics
  • Administration, Oral
  • Animals
  • Antiemetics (administration & dosage, antagonists & inhibitors, toxicity)
  • Benzamides (administration & dosage, antagonists & inhibitors, toxicity)
  • Bridged Bicyclo Compounds (administration & dosage, antagonists & inhibitors, toxicity)
  • Bridged Bicyclo Compounds, Heterocyclic
  • Bridged-Ring Compounds (toxicity)
  • Defecation (drug effects)
  • Dose-Response Relationship, Drug
  • Ferrets
  • Granisetron
  • Indazoles (pharmacology)
  • Injections, Intravenous
  • Male
  • Metoclopramide (administration & dosage, analogs & derivatives, antagonists & inhibitors, toxicity)
  • Pyrazoles (pharmacology)
  • Serotonin (analogs & derivatives, pharmacology)
  • Serotonin Antagonists (pharmacology)
  • Vagotomy
  • Vomiting (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: